Table 2Summary selleck chem PDE inhibitor of pooledfinal results of key and sensitivity analysesResults of sensitivity analyses have been comparable to those of the key evaluation (Table ?(Table2).two). 1st, the evaluation restricted to twelve mixed ICU trials enrolling each surgical and medical sufferers discovered RR = 0.98 (95% CI = 0.80 to 1.19, P = 0.82; I2 = 40%) in surgical patients and RR = 1.03 (95% CI = 0.94 to one.13, P = 0.51; I2 = 8%) in health care individuals (P = 0.66 for comparison of RRs). 2nd, the examination including the outcomes from the 3 surgical ICU trials [32-34] and the three medical ICU trials [35-37] included only during the earlier systematic evaluation  discovered RR = 0.89 (95% CI = 0.74 to one.08, P = 0.24; I2 = 45%) in surgical individuals and RR = one.02 (95% CI = 0.96 to one.09, P = 0.
46; I2 = 0%) in health-related sufferers (P = 0.
18 for comparison of RRs). Finally, the analysis of trials attaining tight glucose Etomidate handle (4 out of eight surgical ICU trials, two from eight healthcare ICU trials, and 5 out of 14 mixed ICU trials) located RR = 0.76 sellckchem (95% CI = 0.57 to one.01, P = 0.06; I2 = 10%) in surgical patients and RR = one.04 (95% CI = 0.71 to 1.53, P = 0.82; I2 = 7%) in healthcare individuals (P = 0.20 for comparison of RRs).